Modipafant

Drug Profile

Modipafant

Alternative Names: 60P 002; UK 80067

Latest Information Update: 29 Dec 2015

Price : $50

At a glance

  • Originator Pfizer
  • Developer 60 Degrees Pharmaceuticals Australia; Pfizer
  • Class Antiasthmatics; Dihydropyridines; Imidazoles; Small molecules
  • Mechanism of Action Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dengue
  • Discontinued Asthma

Most Recent Events

  • 11 Dec 2015 Modipafant licensed to Knight Therapeutics in Canada, Israel and Russia
  • 28 Sep 2015 Phase-I clinical trials in Dengue in USA (unspecified route) (before September 2015)
  • 28 Sep 2015 Discontinued for Asthma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top